Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7-11.032)

To determine the efficacy and safety of 10 mg/kg IV efgartigimod compared with placebo in participants with anti-acetylcholine receptor antibody negative (AChR-Ab−) generalized myasthenia gravis (gMG).

Authors

James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
Sophie Steeland
Fien Gistelinck
Jeff Guptill
Rosa H. Jimenez

Institutions

Argenx (Belgium) (BE)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000210564
Primary Topic: Myasthenia Gravis and Thymoma
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7-11.032)

James F. Howard, Sophie Steeland, Fien Gistelinck, Jeff Guptill et al.

Apr 7, 2025

Neurology

Myasthenia Gravis and Thymoma

article

Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7-11.032)

James F. Howard, Sophie Steeland, Fien Gistelinck, Jeff Guptill, Rosa H. Jimenez

April 7, 2025article en

Abstract

NeurologyVol. 104(7_Supplement_1)

Argenx (Belgium) (BE)

Good health and well-being

Openalex Percentile: Top 88%

Myasthenia Gravis and Thymoma

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis (P7-11.032) — James F. Howard, Sophie Steeland, et al. · Neurology (2025) | TGRS Research Map | TGRS